TG Therapeutics published five year data from the Phase 3 ULTIMATE I & II open label extension studies of BRIUMVI in relapsing multiple sclerosis. The dataset covers thousands of patient years and ...
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of ...
TG Therapeutics continues strong execution with Briumvi, maintaining beat-and-raise performance and robust financials, including a new $100 million buyback program. However, high investor expectations ...
TG Therapeutics exceeded 2024 revenue guidance by 24%, signaling strong growth and market share capture with its Multiple Sclerosis treatment, Briumvi. 2025 revenue guidance of $540 million implies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results